共查询到20条相似文献,搜索用时 0 毫秒
1.
Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity‐modulated radiotherapy 下载免费PDF全文
Ying Sun PhD Yan‐Ping Mao MD Wen‐Fei Li PhD Rui Guo MD Li‐Zhi Liu MD Li Li PhD Ai‐Hua Lin PhD Jun Ma MD 《Head & neck》2014,36(4):468-473
2.
Salvage endoscopic nasopharyngectomy and intensity‐modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma 下载免费PDF全文
Man‐Quan Deng MD Rou Jiang MD Ling Guo MD Qing Liu MD Hai‐Qiang Mai MD PhD Ming‐Huang Hong MD Ming‐Yuan Chen MD PhD 《Head & neck》2015,37(8):1108-1115
3.
Comparative study on prophylactic irradiation to the whole neck and to the upper neck for patients with neck lymph node–negative nasopharyngeal carcinoma 下载免费PDF全文
Chun‐Yan Chen MD Fei Han MD Ying Huang MD Wei‐Wei Xiao MD Shuai Liu MD Yun‐Ming Tian MD Xiao‐Wu Deng PhD Tai‐Xiang Lu MD 《Head & neck》2014,36(5):687-693
4.
Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience 下载免费PDF全文
Irene Karam MD FRCPC Shao Hui Huang MSc MRT MD Andrea McNiven PhD Jie Su MSc Wei Xu PhD John Waldron MD FRCPC Andrew J. Bayley MD FRCPC John Kim MD FRCPC John Cho MD FRCPC Jolie Ringash MD FRCPC Andrew Hope MD FRCPC Eric Chen MD FRCPC Biu Chan MSc David Goldstein MD FRCPC Brian O'Sullivan MD FRCPC Meredith E. Giuliani MD FRCPC 《Head & neck》2016,38(Z1):E1102-E1109
5.
Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity 下载免费PDF全文
Jianhua Xu MD Xia He MD PhD Kong Cheng MD Wenjie Guo MD Xiuhua Bian MD Xuesong Jiang MD Lanfang Zhang MD Shengfu Huang MD 《Head & neck》2014,36(10):1474-1480
6.
7.
Selective omission of level V nodal coverage for patients with oropharyngeal cancer: Clinical validation of intensity‐modulated radiotherapy experience and dosimetric significance 下载免费PDF全文
Pranshu Mohindra MD MBBS Erich Urban PhD Jonathan D. Pagan MD Heather M. Geye MS Vatsal B. Patel MD MBA R. Adam A. Bayliss PhD Edward T. Bender PhD Paul M. Harari MD 《Head & neck》2016,38(4):499-505
8.
9.
Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity‐modulated radiotherapy 下载免费PDF全文
Vinita Takiar MD PhD Dominic Ma BS Adam S. Garden MD Jing Li MD PhD David I. Rosenthal MD Beth M. Beadle MD PhD Steven J. Frank MD Clifton D. Fuller MD Gary B. Gunn MD William H. Morrison MD Kate Hutcheson PhD Adel K. El‐Naggar MD Kathryn A. Gold MD Michael E. Kupferman MD Jack Phan MD PhD 《Head & neck》2016,38(Z1):E925-E933
10.
11.
Mark A. Edson MD PhD Adam S. Garden MD Vinita Takiar MD PhD Bonnie S. Glisson MD Clifton D. Fuller MD PhD Gary B. Gunn MD Beth M. Beadle MD PhD William H. Morrison MD Steven J. Frank MD Shalin J. Shah MD Randa Tao MD William N. William MD Randal S. Weber MD David I. Rosenthal MD Jack Phan MD PhD 《Head & neck》2016,38(Z1):E2091-E2099
12.
13.
Evidence on effectiveness of intensity‐modulated radiotherapy versus 2‐dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta‐analysis and a systematic review of the literature 下载免费PDF全文
Jayson Co MD Michael Benedict Mejia MD Janine Margarita Dizon PhD 《Head & neck》2016,38(Z1):E2130-E2142
14.
Risk of swallowing‐related chest infections in patients with nasopharyngeal carcinoma treated with definitive intensity‐modulated radiotherapy 下载免费PDF全文
Jiaqing Xiong BEng Gita Krishnaswamy MSc MEng Sharon Raynor MSc Kwok Seng Loh FRCS Andrea Lay Hoon Kwa PharmD Chwee Ming Lim MRCS MMed 《Head & neck》2016,38(Z1):E1660-E1665
15.
Reirradiation with intensity‐modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma 下载免费PDF全文
Oscar S. H. Chan FRCR Henry C. K. Sze FRCR Michael C. H. Lee PhD Lucy L. K. Chan BSc Amy T. Y. Chang FRCR Sarah W. M. Lee FRCR Wai Man Hung MSc Anne W. M. Lee MD Wai Tong Ng MD 《Head & neck》2017,39(3):533-540
16.
17.
Intensity‐modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes 下载免费PDF全文
Gary D. Lewis MD Emma B. Holliday MD Esengul Kocak–Uzel MD Mike Hernandez MS Adam S. Garden MD David I. Rosenthal MD Steven J. Frank MD 《Head & neck》2016,38(Z1):E1886-E1895
18.
19.
20.
CHUL JANG KIM YOSHIHIKO WAKABAYASHI RYOJI KUSHIMA YUJI SAKANO TATSUHIRO YOSHIKI YUSAKU OKADA 《International journal of urology》2004,11(4):243-247
Three patients suffered from renal pelvic, ureteral and bladder cancers that were treated with both standard surgical treatments and two adjuvant cycles of cisplatin-based combination chemotherapy. Metastases of interaortocaval lymph nodes were detected in all patients between 9 and 33 months from the surgery for primary lesions. All patients received three cycles of cisplatin-based combination chemotherapy and retroperitoneal lymph node dissection (RPLND). The chemotherapy achieved partial response (62-98%). Two patients with viable cancer cells died with hepatic metastases; the first 15 months and the second 25 months from the date of diagnosis of distant lymph node metastasis. The third patient, who had no viable cancer cells, remains alive and disease-free 36 months later. Therefore, RPLND after chemotherapy provides prognostic information that helps to define patients who might benefit from additional systemic chemotherapy. 相似文献